Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 4, 2008, Pages 692-700

  Xu, Shang Zhong ^a   Zhong, W ^a   Watson, N M ^a   Dickerson, E ^a   Wake, J D ^a   Lindow, S W ^b   Newton, C J ^a   Atkin, S L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; Cell proliferation; Endothelial cells; Fluvastatin; Hydrogen peroxide; TRPM2

Indexed keywords

CLUSTERIN; FLUINDOSTATIN; HOE 33342; HYDROGEN PEROXIDE; PROTEIN BCL 2; SMALL INTERFERING RNA; TRYPAN BLUE;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL DIVISION; CELLS, CULTURED; DNA DAMAGE; ENDOTHELIAL CELLS; FATTY ACIDS, MONOUNSATURATED; GENES, BCL-2; HUMANS; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; NECROSIS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TRPM CATION CHANNELS; UMBILICAL VEINS; UP-REGULATION;

EID: 40949118011     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02913.x     Document Type: Article

References (34)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
2. Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M, Monopoli A, Del Soldato P, Ignarro LJ. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 2004; 101: 8497-502.
3. Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 2006; 98: 34P-41P.
4. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002; 277: 15309-16.
5. Cai H. Hydrogen peroxide regulation of endothelial function: Origins, mechanisms, and consequences. Cardiovasc Res 2005; 68: 26-36.
6. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440: 944-8.
7. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H, Iguchi A. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155: 347-57.
8. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107: 106-12.
9. Baetta R, Camera M, Comparato C, Altana C, Ezekowitz MD, Tremoli E. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2002; 22: 692-8.
10. Tiefenbacher CP, Kapitza J, Dietz V, Lee CH, Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol 2003; 285: H59-64.
11. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-73.
12. Wei H, Fang L, Song J, Chatterjee S. Statin-inhibited endothelial permeability could be associated with its effect on PECAM-1 in endothelial cells. FEBS Lett 2005; 579: 1272-8.
13. Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 2003; 170: 237-43.
14. Newton CJ, Ran G, Xie YX, Bilko D, Burgoyne CH, Adams I, Abidia A, McCollum PT, Atkin SL. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 2002; 174: 7-16.
15. Schaefer CA, Kuhlmann CR, Weiterer S, Fehsecke A, Abdallah Y, Schaefer C, Schaefer MB, Mayer K, Tillmanns H, Erdogan A. Statins inhibit hypoxia-induced endothelial proliferation by preventing calcium-induced ROS formation. Atherosclerosis 2006; 185: 290-6.
16. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
17. Xu SZ, Zeng F, Lei M, Li J, Gao B, Xiong C, Sivaprasadarao A, Beech DJ. Generation of functional ion-channel tools by E3 targeting. Nat Biotechnol 2005; 23: 1289-93.
18. 2+ channels in native vascular smooth muscle cells. Circ Res 2001; 88: 84-7.
19. Xu SZ, Muraki K, Zeng F, Li J, Sukumar P, Shah S, Dedman AM, Flemming PK, McHugh D, Naylor J, Cheong A, Bateson AN, Munsch CM, Porter KE, Beech DJ. A sphingosine-1-phosphate-activated calcium channel controlling vascular smooth muscle cell motility. Circ Res 2006; 98: 1381-9.
20. Xu SZ, Sukumar P, Zeng F, Li J, Jairaman A, English A, Naylor J, Ciurtin C, Majeed Y, Milligan CJ, Bahnasi YM, Al-Shawaf E, Porter KE, Jiang LH, Emery P, Sivaprasadarao A, Beech DJ. TRPC channel activation by extracellular thioredoxin. Nature 2008; 451: 69-72.
21. Demaurex N, Distelhorst C. Cell biology. Apoptosis-the calcium connection. Science 2003; 300: 65-7.
22. Hetz C, Bernasconi P, Fisher J, Lee AH, Bassik MC, Antonsson B, Brandt GS, Iwakoshi NN, Schinzel A, Glimcher LH, Korsmeyer SJ. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science 2006; 312: 572-6.
23. 2+ dependence of transient receptor potential melastatin 2 (TRPM2) cation channel activation. J Biol Chem 2003; 278: 11002-6.
24. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-81.
25. Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, Chang J, Wang S, Wang CY, Strieter RM, Nunez G, Polverini PJ, Nor JE. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 2005; 65: 5063-9.
26. Karbowski M, Norris KL, Cleland MM, Jeong SY, Youle RJ. Role of Bax and Bak in mitochondrial morphogenesis. Nature 2006; 443: 658-62.
27. Lee YJ, Kang IJ, Bunger R, Kang YH. Mechanisms of pyruvate inhibition of oxidant-induced apoptosis in human endothelial cells. Microvasc Res 2003; 66: 91-101.
28. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-45.
29. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 2007; 50: 409-18.
30. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105.
31. Ayalasomayajula SP, Vaidyanathan S, Kemp C, Prasad P, Balch A, Dole WP. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin. J Clin Pharmacol 2007; 47: 613-9.
32. Muck AO, Seeger H, Wallwiener D. Class-specific pro-apoptotic effect of statins on human vascular endothelial cells. Z Kardiol 2004; 93: 398-402.
33. Inoue T, Hayashi M, Takayanagi K, Morooka S. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 2002; 160: 369-76.
34. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ, Egido J. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002; 161: 17-26.